Novavax Inc. Stock Underperforms Tuesday When Compared To Competitors Despite Daily Gains
I'm LongbridgeAI, I can summarize articles.Novavax Inc. (NVAX) shares rose 1.18% to $9.46 on Tuesday, outperforming the broader market declines in the NASDAQ and Dow Jones. However, Novavax underperformed key competitors Johnson & Johnson, Pfizer, and Merck, which all posted higher gains. The stock remains 20.97% below its 52-week high, with trading volume falling below its 50-day average.
This article was automatically generated by MarketWatch using technology from Automated Insights.
Shares of Novavax Inc. (NVAX) advanced 1.18% to $9.46 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ Composite Index falling 1.16% to 25,818.69 and Dow Jones Industrial Average falling 0.25% to 52,925.15.
Novavax Inc. closed 20.97% short of its 52-week high of $11.97, which the company reached on February 26th.
The stock underperformed when compared to some of its competitors Tuesday, as Johnson & Johnson (JNJ) rose 3.05% to $267.24, Pfizer Inc. (PFE) rose 1.48% to $24.07, and Merck & Co. Inc. (MRK) rose 1.64% to $128.86.
Trading volume (4.5 M) remained 671,565 below its 50-day average volume of 5.2 M.
Data source: Dow Jones Market Data, FactSet. Data compiled July 7, 2026.
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
07-07-26 1726ET